medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2002, Número 1

<< Anterior Siguiente >>

Rev Inst Nal Enf Resp Mex 2002; 15 (1)


Alteraciones de la glicosilación en enfermedades humanas

Jiménez MMC, Trejo MH, Herrera SA, Romero IJL, Chávez R, Lascurain R, Zenteno E

Idioma: Español
Referencias bibliográficas: 59
Paginas: 39-47
Archivo PDF: 563.77 Kb.


RESUMEN

Los glicoconjugados intervienen en diversos procesos biológicos. Cambios en los procesos de glicosilación, generan trastornos en las funciones biológicas que realizan. Las alteraciones en la glicosilación pueden ser congénitamente determinadas, adquiridas o no enzimáticas. En este trabajo, se revisan los mecanismos de glicosilación que se encuentran alterados en diversas enfermedades humanas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Jürgen R. Subcellular organization of glycosylation in mammalian cells. BBA 1987;405-436.

  2. Hakomori.S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 1985;45:2405-2414.

  3. Lis H, Sharon N. Protein glycosylation. Structural and functional aspects. Eur J Biochem 1993;218:1-27.

  4. Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J. Essentials of glycobiology. Protein-Glycan interactions. Cold Spring Harbor Laboratory Press 1999;41-59.

  5. Zannetta JP, Kuchler S, Lehmann S, Badache A, Maschke S, Tomas D, et al. Glycoproteins and lectins in cell adhesion and recognition processes. Histochem J 1992;24:791-804.

  6. Schenk B, Imbach T, Frank Ch, Grubenmann C, Raymond G, Hurvitz H, et al. MPDU1 mutations underlie a novel human congenital disorder of glycosylation, designated type If. J Clin Invest 2001;108:1687-1695.

  7. Yamashita K, Ideo H, Ohkura T, Fukushima K, Yuasa I, Ohno K, et al. Sugar chains of serum . J Biol Chem 1993; 268:5783-5789.

  8. Schachter H. The clinical relevance of glycobiology. J Clin Invest 2001; 108:1579-1582.

  9. Kjaergaard S, Schwartz M, Skovby F. Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H/F119L genotype. Arch Dis Child 2001;85:236-239.

  10. Ornstein KS, McGuire EJ, Berry GT, Roth S, Segal S. Abnormal galactosylation of complex carbohydrates in cultured fibroblasts from patients with galactose-1-phosphate uridyltransferase deficiency. Pediatr Res 1992;31:508-511.

  11. Jaeken J, Pirard M, Adamowicz M, Pronicka E, Van Schaftingen E. Inhibition of phosphomannose isomerase by fructose 1-phosphate: an explanation for defective N-glycosylation in hereditary fructose intolerance. Pediatr Res 1996; 40:764-766.

  12. Lopes AI, Almeida AG, Costa AE, Costa A, Leite M. Hereditary fructose intolerance. Acta Med Port 1998;11:1121-1125.

  13. Horwitz BH, Mizgerd JP, Scott ML, Doerschuk CM. Mechanisms of granulocytosis in the absence of CD18. Blood 2001;97:1578-1583

  14. Alon R, Chen S, Fuhlbrigge R, Puri KD, Springer TA. The kinetics and shear threshold of transient and rolling interactions of L-selectin with its ligand on leukocytes. Proc Natl Acad Sci USA 1998;95:11631-11636.

  15. Schachter H. Congenital disorders involving defective N-glycosylation of proteins. Cell Mol Life Sci 2001;58:1085-1104.

  16. Charuk J, Tan J, Bernardini M, Haddad S, Reitheiner R, Jaeken J, et al. Carbohydrate-deficient glycoprotein syndrome type II-An autosomal recessive N-acetylglucosminyltransferasa II deficiency different from typical hereditary erytroblastic multinuclearity, with a positive acidified-serum lysis test (HEMPAS). Eur J Biochem 1995; 230:797-805.

  17. Chui D, Oh-Eda M, Liao YF, Panneerselvam P, Lai A, Marek K. a-mannosidase-II deficiency results in dyserythropoiesis and unveils an alternate pathway in oligosaccharide biosynthesis. Cell 1997;90:157-167.

  18. Yagev H, Frenkel A, Cohen IR, Friedman A. Adjuvant arthritis is associated with changes in the glycosylation of serum IgG1 and IgG2b. Clin Exp Immunol 1993;94:452-458.

  19. Axford JS, Sumar N, Alavi A, Isenberg DA, Young A, Bodman KB, et al. Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J Clin Invest 1992; 89:1021-1031.

  20. Kobata A. Structural changes induced in the sugar chains of glycoproteins by malignant transformation of producing cells and their clinical application. Biochimie 1988;70:1575-1585.

  21. Motte P, Takahashi H, Ozturk M, Wilson BE, Wands JR. Characterization of a malignant phenotype-associated cell surface glycoprotein common to various human tumor cells and preferentially expressed on adenocarcinoma of the lung. Cancer Res 1989;49:1349-1356.

  22. Gromova I, Gromov P, Celis JE. A novel member of the glycosyltransferase family, beta 3 Gn-T2, highly downregulated in invasive human bladder transitional cell carcinomas. Mol Carcinog 2001;32:61-72.

  23. Nihlen U, Montnemery P, Lindholm LH, Lofdahl CG. Increased serum levels of carbohydrate-deficient transferrin in patients with chronic obstructive pulmonary disease. Scand J Clin Lab Invest 2001;61:341-347.

  24. Mackiewicz A, Khan MA, Gorny A, Kapcinska M, Juszczyk J, Calabrese LH, et al. Glycoforms of alpha 1-acid glycoprotein in sera of human immunodeficiency virus-infected persons. J Infect Dis 1994;169:1360-1363.

  25. Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995;100:470-474.

  26. Chintalacharuvu SR, Nagy NU, Sigmund N, Nedrud JG, Amm ME, Emancipator SN. T cell cytokines determine the severity of experimental IgA nephropathy by regulating IgA glycosylation. Clin Exp Immunol 2001;126:326-333.

  27. Derry JM, Kerns JA, Weinberg KI, Ochs HD, Volpini V, Estivill X, et al. WASP gene mutations in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Hum Mol Genet 1995;4:1127-1135

  28. Durand G, Seta N. Protein glycosylation and diseases: Blood and urinary oligosaccharides as markers for diagnosis and therapeutic monitoring. Clin Chem 2000;46:795-805.

  29. Greer WL, Higgins E, Sutherland DR, Novogrodsky A, Brockhausen I, Peacocke M. Altered expression of leucocyte sialoglycoprotein in Wiskott-Aldrich syndrome is associated with a specific defect in O-glycosylation. Biochem Cell Biol 1989;67:503-509.

  30. Copin MC, Devisme L, Buisine MP, Marquette CH, Wurtz A, Aubert JP. From normal respiratory mucosa to epidermoid carcinoma: expression of human mucin genes. Int J Cancer 2000;86:162-168.

  31. Meichenin M, Rocher J, Galanina O, Bovin N, Nifantev N, Sherman A, et al. Tk, a new colon tumor-associated antigen resulting from altered O-glycosylation. Cancer Res 2000;60:5499-5507.

  32. Babino A, Oppezzo P, Bianco S, Barrios E, Berois N, Navarrete H, et al. Tn antigen is a pre-cancerous biomarker in breast tissue and serum in n-nitrosomethylurea-induced rat mammary carcinogenesis. Int J Cancer 2000 15;86:753-759.

  33. Gum JR. Mucin genes and the proteins they encode: structure, diversity, and regulation. Am J Respir Cell Mol Biol 1992;7:557-564.

  34. Carraway KL, Hull SR. Cell surface mucin-type glycoproteins and mucin-like domains. Glycobiology 1991;1:131-138.

  35. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-574.

  36. Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, Guggino WB. CFTR is a conductance regulator as well as a chloride channel. Physiol Rev 1999;79(1Suppl):145S-166S.

  37. Davril M, Degroote S, Humbert P, Galabert C, Dumur V, Lafitte JJ, et al. The sialylation of bronchial mucins secreted by patients suffering from cystic fibrosis or from chronic bronchitis is related to the severity of airway infection. Glycobiology 1999;9:311-321.

  38. Delmotte P, Degroote S, Lafitte JJ, Lamblin G, Perini JM, Roussel P. Tumor necrosis factor alpha increases the expression of glycosyltransferases and sulfotransferases responsible for the biosynthesis of sialylated and/or sulfated Lewis x epitopes in the human bronchial mucosa. J Biol Chem 2002;277:424-431.

  39. Jiménez MC, Báez R, Andrade A, Torres J, Chávez R, Lascurain R, et al. Increased O-glicoprotein expression on CD4+T cells in human tuberculosis. Glyco XVI. The Hague 2001: 76.

  40. Garfias Y, Rojas E, Lascurain R, Chávez R, Martínez-Cairo S, Zenteno E. Differences on the expression of an O-glycosylprotein on CD4+ T cells, compared with phenotypic cell surface markers on different atopic diseases. Glyco XVI. The Hague 2001: 76.

  41. Zenteno E, Lascurain R, Montaño L, Vázquez L, Debray H. Specificity of Amaranthus leucocarpus lectin. Glycoconj J 1992; 9:204-208.

  42. Singh R, Barden A, Mori T, Beilin L Advanced glycation end-products: a review. Diabetologia 2001;44:129-146.

  43. Brownlee M. The pathological implications of protein glycation. Clin Invest Med 1995;18:275-281.

  44. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.

  45. Schmidt AM, Du Yan S, Wautier JL, Stern D. Activation of receptor for advanced glycaton end products. A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;89:489-497.

  46. Wautier JL, Wautier MP, Schmidt AM, Anderson M, Hori O, Zoukourian C, et al. Advanced glycation end products (AGEs) on the surface of diabetic erytrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci. USA 1994; 91:7742-7746.

  47. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994;14:1521-1528.

  48. Lander H, Taurast J, Ogiste J, Hori O, Moss R, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21 ras-dependent Mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17810-17814.

  49. Picard S. Lipoprotein glyco-oxidation. Diabete Metab 1995;21:89-94.

  50. Munch G, Thome J, Foley P, Schinzel R, Riederer P. Advanced glycation endproducts in ageing and Alzheimer’s disease. Brain Res Brain Res Rev 1997;23:134-143.

  51. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, et al. Glycated tau protein in Alzheimer’s disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994;91:7787-7791.

  52. Sato Y, Naito Y, Grundke-Iqbal I, Iqbal K, Endo T. Analysis of N-glycans of pathological tau: possible occurrence of aberrant processing of tau in Alzheimer´s. FEBS Letters 2001;496:152-160.

  53. Espinosa B, Zenteno R, Mena R, Robitaille Y, Zenteno E, Guevara J. O-glycosylation in sprouting neurons in Alzheimer disease, indicating reactive plasticity. J Neuropathol Exp Neurol 2001;260:441-448.

  54. Nicholl ID, Bucala R. Advanced glycation endproducts and cigarette smoking. Cell Mol Biol 1998;44:1025-1033.

  55. Varki a, Marth J. Olgosaccharides in vertebrate development. Sem Developmental Biol 1995 6:127-138.

  56. Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J. Essentials of glycobiology. Historical background and overview. Cold Spring Harbor Laboratory Press 1999;1-15.

  57. Hassanein AM, Al-Quran SZ, Kantor GR, Pauporte M, Telang GH, Spielvogel RL. Thomsen-Friedenreich (T) antigen: a possible tool for differentiating sebaceous carcinoma from its simulators. Appl Immunohistochem Mol Morphol 2001;9:250-254.

  58. Turner GA. N-glycosylation of serum proteins in disease and its investigation using lectins. Clin Chim Acta 1992;208:149-171.

  59. Nawroth PP, Bierhaus A, Vogel GE, Hofmann MA, Zumbach M, Wahl P, et al. Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus Med Klin 1999;94:29-38.




2020     |     www.medigraphic.com